Compare YieldMax TSLA Option Income Strategy ETF (TSLY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax TSLA Option Income Strategy ETF vs Zimmer Biomet Holdings Inc — how do they compare? YieldMax TSLA Option Income Strategy ETF trades at $22.45 (market cap $697.51M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 24.3× YieldMax TSLA Option Income Strategy ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while YieldMax TSLA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax TSLA Option Income Strategy ETF for 43 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TSLY | ZBH | |
|---|---|---|
Market Cap | $697.51M | $16.95B |
Volume | 338,271 | 2,505,240 |
Sector | Income / Options Overlay | Health |
52-Week High | $43.35 | $103.98 |
52-Week Low | $20.49 | $79.58 |
Typical Hold Time | 43 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLY trades at $22.45, down 0.66% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent analysis highlights concerns about missing Tesla's upside potential. Support levels cluster around $22 with resistance at $23-24, while RSI indicators remain neutral.
The outlook remains mixed with high yield appeal balanced against structural limitations in capturing Tesla's gains. Key risks include Tesla's volatility regime changes and the ETF's option income strategy constraints. Recent analyst downgrades to Hold reflect diminished upside capture potential amid Tesla's extended capex cycle.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
